Skip to main content
. 2020 Feb 28;23(3):517–526. doi: 10.1038/s41391-020-0213-7

Fig. 1. OS in the subset of PSA-matched African American and Caucasian men with mCRPC treated with sipuleucel-T in PROCEED for all included patients.

Fig. 1

Median OS estimates indicated by vertical dash-dot lines. CI confidence interval, HR hazard ratio, OS overall survival, PSA prostate-specific antigen.